In vitro and in vivo assessment of the bioavailability of potassium from a potassium tartrate tablet

Biopharm Drug Dispos. 1991 Apr;12(3):207-13. doi: 10.1002/bdd.2510120305.

Abstract

The bioavailability of potassium from orally administered potassium tartrate was evaluated in 20 normal subjects under metabolic balance conditions. Subjects were given 34 mmol potassium (5 tablets of Cal-K) as a divided dose on each of 2 consecutive days. Urinary excretion of potassium, as determined from 24-h urinary collections on the 3 days preceding dosage totalled 192.6 +/- 50.9 mmol (mean +/- S.D., n = 20). It increased significantly (p less than 0.05) to 258.7 +/- 54.2 mmol for the 2 days of dosage and the following day. The difference of 66.1 mmol representing absorbed potassium was close to the 68 mmol potassium given and indicated a bioavailability of potassium in excess of 97 per cent; after correction for creatinine excretion, potassium recovery rose to 99.9 per cent. The dissolution characteristics of the Cal-K tablets were also determined. After dissolution in simulated gastric juice (pH 1.2), 84.4 +/- 10.6 per cent (mean +/- S.D., 6 experiments) was dissolved; after adjustment to pH 7.3, dissolved potassium increased to 91.3 +/- 8.5 per cent. No precipitation or residue formed as a result of the pH change. Both sets of results indicate that potassium from these potassium tartrate tablets is in a highly bioavailable form.

MeSH terms

  • Adult
  • Biological Availability
  • Creatinine / urine
  • Female
  • Gastric Acid
  • Humans
  • Hydrogen-Ion Concentration
  • Intestine, Small / metabolism
  • Male
  • Potassium / administration & dosage
  • Potassium / pharmacokinetics*
  • Potassium / urine
  • Sodium / urine
  • Solubility
  • Tablets
  • Tartrates / administration & dosage
  • Tartrates / pharmacokinetics*

Substances

  • Tablets
  • Tartrates
  • Sodium
  • Creatinine
  • Potassium
  • tartaric acid